Phase III randomised double-blind controlled trial of oral risperidone, haloperidol or placebo with rescue subcutaneous midazolam for delirium management in palliative care

Authors

Meera Agar, Braeside Hospital, Sydney South West Area Health Service
Peter Lawlor, University of Ottawa
Stephen Quinn, Flinders University
Gideon Caplan, University of New South Wales
Brian Draper, University of New South Wales
Debra Rowett, Flinders University
Linda Devilee, Flinders University
Belinda Fazekas, Flinders University
Christine Sanderson, Hammond Care
N Mccaffery, Flinders University
Janet Hardy, University of Queensland
Brian Le, University of Melbourne
Simon Eckermann, University of WollongongFollow
Mark Hill, University of New South Wales
David C. Currow, Flinders University, Cancer Institute New South Wales

RIS ID

101303

Publication Details

Agar, M., Lawlor, P., Quinn, S., Caplan, G., Draper, B., Rowett, D., Devilee, L., Fazekas, B., Sanderson, C., McCaffery, N., Hardy, J., Le, B., Eckermann, S., Hill, M. & Currow, D. (2015). Phase III randomised double-blind controlled trial of oral risperidone, haloperidol or placebo with rescue subcutaneous midazolam for delirium management in palliative care. Australasian Journal on Ageing, 34 (Issue Supplement S1), 33-33.

Abstract

Aims: Guidelines recommend targeted use of antipsychotics in delirium for specific symptoms however this approach has not been evaluated in randomised trials. To compare the efficacy of risperidone relative to placebo in the control of specific delirium symptoms in palliative care patients (communication, behaviour and/or perceptual disturbances on Nursing Delirium Screening Scale) at 72 hours after study commencement. Secondary aims were to compare haloperidol and placebo; and risperidone and haloperidol.